Pazan, Farhad http://orcid.org/0000-0003-3434-3573
Wehling, Martin
Weiss, Christel
Frohnhofen, Helmut
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (WE 1184/15-1, FR2997/2-1)
Ruprecht-Karls-Universität Heidelberg
Article History
Received: 4 January 2023
Accepted: 3 April 2023
First Online: 19 April 2023
Declarations
:
: HF received a grant from Paul-Kurth-Stiftung. MW was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Bristol Myers, Bayer, Boehringer-Ingelheim, LEO, Mundipharma, Novartis, Pfizer, Polyphor, Helsinn, Allergan, Allecra, Novo-Nordisk, Heel, AstraZeneca, Roche, Santhera, Sanofi-Aventis, Shire, Berlin-Chemie, and Daichii-Sankyo. CW and FP have no COIs to declare.
: The study was approved by the Ethics Committee of the Medical Faculty Mannheim, Heidelberg University and the Ethics Committee of the University of Witten-Herdecke.
: Informed consents were obtained.